Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

Aedes aegypti mosquitoes that spread dengue, chikungunya and Zika are showing resistance to permethrin, a commonly used pyrethroid insecticide, in parts of Pune, according to a new ICMR-National Institute of Virology (NIV) study.

The finding, published as preprint in the International Journal of Tropical Insect Science, raises concerns about the effectiveness of insecticide-based mosquito control, particularly during outbreaks.

Researchers collected Aedes aegypti mosquitoes from nine Pune Municipal Corporation wards — Pashan, Susgaon, Khadki, Yerawada, Warje, Hadapsar, Kondhwa, Kothrud and Dhankawdi — between February and May 2024.

They exposed the mosquitoes to 0.75% permethrin, the standard dose used in WHO susceptibility testing.

Resistance was detected in mosquitoes from six of the nine localities, while mosquitoes from three wards remained susceptible.

Genetic Mutations Linked to Resistance

The researchers then used PCR amplification and Sanger sequencing to look for genetic changes associated with pyrethroid resistance.

They identified four previously reported mutations:

• S989P and V1016G in Pashan and Kondhwa
• F1534C in Khadki, Susgaon, Warje, Yerawada and Hadapsar
• T1520I exclusively in Hadapsar

The D1763Y mutation, which can occur alongside V1016G, was not detected. The differences in mutations across wards suggest that resistance mechanisms may vary between mosquito populations.

Why Are Mosquitoes Becoming Resistant?

Pyrethroid resistance can develop through metabolic changes, target-site mutations, or both. Target-site changes, known as knockdown resistance (kdr) mutations, can reduce the ability of pyrethroids to act on the mosquito's voltage-gated sodium channel.

Pyrethroids have been widely used in India for mosquito control since the 1980s. Reduced susceptibility to deltamethrin, lambda-cyhalothrin and permethrin has also been reported in several states, including Assam, Delhi, West Bengal and Rajasthan.

The researchers noted that the widespread use of pyrethroid-based household mosquito-control products, including vaporizers, mats and coils, could potentially contribute to resistance.

What Does This Mean for Public Health?

According to the WHO South-East Asia Region Epidemiological Bulletin which reported 22,938 dengue cases in India through June 2026.

When mosquitoes develop resistance, more of them can survive exposure to insecticides that would normally kill susceptible mosquitoes. This could make controlling Aedes aegypti more difficult, particularly during dengue outbreaks.

Importantly, insecticide resistance does not mean the mosquitoes cause more severe dengue. The concern is that commonly used mosquito-control measures may become less effective.

The researchers called for regular resistance surveillance, insecticide rotation and locally tailored integrated vector-management strategies.

Did Insecticide Spraying Cause the Resistance?

The researchers noted that areas reporting more dengue cases may have experienced more frequent insecticide spraying, which could potentially be associated with higher resistance.

However, the study did not directly track insecticide use in these areas and did not establish that spraying caused the resistance.

The researchers stressed the need for continued surveillance to track resistance and adapt mosquito-control strategies to local conditions.

Future research could examine resistance genes through genetic mapping, transcriptomic profiling and CRISPR-Cas9 studies, while studying behavioral changes that may help mosquitoes survive insecticide exposure.

Cancer cases linked to the September 11, 2001, World Trade Center terror attacks have surged 75%, according to new research, highlighting the ongoing health crisis even 25 years later.

The research was conducted by Northwell Health’s Long Island Jewish (LIJ) Medical Center, which provides free medical monitoring to people affected by the aftermath of the attacks at New York’s World Trade Center, where nearly 3,000 people were killed.

About two-thirds of all enrollees are certified for at least one WTC-related health condition, while 30% of those enrolled through Northwell have battled cancer. That number is expected to rise dramatically over the next decade.

“For over 25 years, we have cared for people who were exposed to the aftermath of September 11th,” said Jacqueline Moline, director of the Northwell WTC Health Program.

“Over 57,000 cases of cancer have been documented, and cancer rates — including rare cancers — are rising. There has been a two-fold increase in lung cancer in just five years. Our fear is that cancer diagnoses will only rise as we move into the next 25 years.”

Which Cancers Are Growing?

Northwell’s WTC Health Program saw 9/11-certified cancer cases increase from 177 in 2023 to 235 in 2025 — a 75% jump over three years.

Another 132 new cases were reported through the first half of 2026, continuing the trend. That brings the total to 811 new cases over 42 months.

Prostate and skin cancers were the most common, followed by breast and urinary tract cancers.

By comparison, the program recorded 1,634 cancer cases during the first decade from 2013 to 2022, and 2,445 all-time cases through June among 1,489 people.

Crisis Grows From Lung Diseases To Cancer

Researchers at the center noted that September 11 was not a one-day event. The toxic dust cloud at Ground Zero and the gruelling recovery work created a persistent environmental catastrophe that continues to affect lives.

A variety of lung diseases were seen earlier among those affected. Now, after a decades-long incubation, a range of cancers is emerging as a growing concern.

"Hundreds of thousands of people were at risk then and remain at risk for disease now. While we initially saw respiratory disease, we now are faced with increasing numbers of our patients developing cancer," Moline said.

Further, a trove of newly released files by New York City Mayor Zohran Mamdani indicates that toxic air persisted for months after the 9/11 attacks on the World Trade Center and that officials played down the health risks.

“People got sick because the leaders they trusted lied and told them they were safe to breathe in toxic air,” Mamdani said at a news conference with survivors.

“As the years pass and the human toll grows, we reckon with the cost of September 11th whenever another New Yorker is stolen from us too soon. Now, close to 25 years later, more people have died from 9/11-related illnesses than were killed on the day itself.

Google DeepMind has launched AlphaGenome Atlas, an AI-powered database that maps the predicted effects of all 9 billion possible single-letter changes in the human genome.

The novel tool could help scientists identify genetic changes linked to rare diseases, understand how mutations affect gene function and uncover new clues about human health and disease.

AlphaGenome Atlas: Explore DNA We Don’t Understand

Scientists have a strong understanding of the roughly 2% of the genome that codes for proteins. But interpreting mutations in the remaining 98% of non-coding regulatory DNA has been much more difficult.

Changes in these regions can disrupt how genes are regulated and affect cellular functions. By pre-computing the predicted effects of billions of genetic variations, AlphaGenome Atlas aims to give researchers a map for navigating this largely unexplored part of the genome.

The resource could help researchers investigate unsolved rare diseases, uncover biological mechanisms behind common illnesses and support drug discovery.

Also read:EXCLUSIVE: GLP-1 Drugs Are The ‘New Statins’, Says University Hospital Birmingham Professor

One Score to Help Researchers Prioritize Variants

The Atlas introduces the AlphaGenome Variant Impact (AVI) score, a single score that combines predictions for genetic effects across coding and non-coding regions.

This allows researchers to prioritize potentially important variants without having to sift through thousands of individual data points.

Each AVI score is also linked to the biological features contributing to the prediction, including aspects of gene regulation predicted by AlphaGenome and protein-impact information from AlphaMissense.

A Genetic Database

AlphaGenome Atlas contains predictions for the effects of 9 billion single-nucleotide variants in the human genome.

The dataset is about 1 petabyte in size, making it more than 30 times larger than the previous AlphaFold Database.

The Atlas brings together several resources, including:

• Molecular effect predictions: Thousands of predictions for each variant across multiple aspects of gene regulation, covering hundreds of human and mouse cell types and tissues.
• AVI score: A single score indicating the predicted impact of each genetic variant.
• AVI feature attributions: Information showing the biological features driving each AVI score.
• DNA sequence motifs: A collection of more than 2,500 recurrent DNA sequences and their locations in the genome.

Helping Solve Rare Genetic Diseases

Read More: HHS Announces US FDA’s First AI Chief: Here’s What It Means For The Future Of Drug Regulation

One of the biggest challenges in rare disease research is identifying the few potentially causal variants among thousands of genetic changes.

Researchers at the Broad Institute, working with the GREGoR Consortium, used the AVI score to prioritise variants in unsolved rare disease cases and identified a variant affecting the DNM1 gene which is strongly linked to epileptic encephalopathy.

Finding Genetic Links To Complex Traits

AlphaGenome Atlas is also being used to study rare, non-coding variants linked to complex traits, where the large number of harmless genetic changes can create substantial statistical noise.

Researchers at the University of Exeter applied the Atlas to identify 22% more non-coding genetic associations.

Among the top 1% of variants predicted to have the greatest impact, the analysis identified 19 genetic regions linked to body mass index (BMI), helping direct further targeted research.

AlphaGenome Atlas Is Free For Research

Google DeepMind said AlphaGenome Atlas is being made free to the scientific community for academic research, with the aim of opening new pathways for genetic and biomedical discovery.

The company described it as a comprehensive catalogue of how genetic mutations are predicted to affect molecular biology, covering every possible single-letter genetic change across the human genome.